Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2017

27.10.2016 | Preclinical study

Up-regulation of cathepsin S expression by HSP90 and 5-HT7 receptor-dependent serotonin signaling correlates with triple negativity of human breast cancer

verfasst von: Jaya Gautam, Young Kyung Bae, Jung-Ae Kim

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cathepsin S (CTSS) is expressed in a variety of cancers and stimulates tumor progression. However, the regulatory mechanism and role of CTSS in breast cancer progression are poorly understood. The aim of this study was to examine the relationships between CTSS expression and breast cancer grade and stage, and the signaling molecules involved in CTSS expression.

Methods

Immunohistochemical staining was performed in tissue microarray sections of 1451 human invasive breast cancer samples to determine epithelial (E-CTSS) and stromal CTSS (S-CTSS) expression. Gene and protein expression levels in human breast cancer cell lines were measured by polymerase chain reaction and western blotting. Small interfering RNA transfection and a Matrigel transwell invasion assay were used to confirm the signaling pathways regulating CTSS expression.

Results

In patient tumor tissue blocks, high grade, late stage, and triple negativity were associated with elevated CTSS protein expression, and expression levels were related to the clinical outcomes of patients with invasive breast cancer. CTSS expression was also higher in triple-negative breast cancer (TNBC) cell lines than in hormone-responsive cells, and CTSS expression patterns matched those of tryptophan hydroxylase 1 (TPH1) and 5-hydroxytryptamine receptor 7 (5-HT7). Treatment of TNBC cells (MDA-MB-231 and HCC-1395) with 5-HT significantly enhanced CTSS protein expression, whereas pharmacological inhibition or knockdown of 5-HT7 significantly inhibited its expression. Correspondingly, cancer cell invasion was increased by 5-HT treatment and suppressed by 5-HT7 knockdown. The expression of CTSS was regulated by PI3K/Akt and Ras/Raf/MAPK signaling pathways, and these signaling pathways were stabilized by HSP90 and enhanced by the 5-HT7 receptor-dependent autocrine effect of 5-HT in TNBC cells.

Conclusion

Our findings suggest CTSS as a candidate target for development of a strategy to inhibit breast cancer invasion, and indicate that HSP90 and 5-HT7 (regulators of CTSS) should be considered as alternative targets for the management of TNBC invasion and metastasis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Gocheva V, Joyce JA (2007) Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6(1):60–64CrossRefPubMed Gocheva V, Joyce JA (2007) Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6(1):60–64CrossRefPubMed
3.
Zurück zum Zitat Yang Y, Lim S-K, Choong L-Y, Lee H, Chen Y, Chong P-K, Ashktorab H, Wang TT, Salto-Tellez M, Yeoh K-G (2010) Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins. J Proteome Res 9(12):6801CrossRef Yang Y, Lim S-K, Choong L-Y, Lee H, Chen Y, Chong P-K, Ashktorab H, Wang TT, Salto-Tellez M, Yeoh K-G (2010) Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins. J Proteome Res 9(12):6801CrossRef
4.
Zurück zum Zitat Gormley J, Hegarty S, O’Grady A, Stevenson M, Burden R, Barrett H, Scott C, Johnston J, Wilson R, Kay E (2011) The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study. Br J Cancer 105(10):1487–1494CrossRefPubMedPubMedCentral Gormley J, Hegarty S, O’Grady A, Stevenson M, Burden R, Barrett H, Scott C, Johnston J, Wilson R, Kay E (2011) The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study. Br J Cancer 105(10):1487–1494CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Sage J, Mallèvre F, Barbarin-Costes F, Samsonov SA, Gehrcke J-P, Pisabarro MT, Perrier E, Schnebert S, Roget A, Livache T (2013) Binding of chondroitin 4-sulfate to cathepsin S regulates its enzymatic activity. Biochemistry 52(37):6487–6498CrossRefPubMed Sage J, Mallèvre F, Barbarin-Costes F, Samsonov SA, Gehrcke J-P, Pisabarro MT, Perrier E, Schnebert S, Roget A, Livache T (2013) Binding of chondroitin 4-sulfate to cathepsin S regulates its enzymatic activity. Biochemistry 52(37):6487–6498CrossRefPubMed
6.
Zurück zum Zitat Shi G-P, Webb AC, Foster KE, Knoll J, Lemere CA, Munger JS, Chapman HA (1994) Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J Biol Chem 269(15):11530–11536PubMed Shi G-P, Webb AC, Foster KE, Knoll J, Lemere CA, Munger JS, Chapman HA (1994) Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J Biol Chem 269(15):11530–11536PubMed
7.
Zurück zum Zitat Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA (2006) Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20(5):543–556CrossRefPubMedPubMedCentral Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA (2006) Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20(5):543–556CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Burden RE, Gormley JA, Jaquin TJ, Small DM, Quinn DJ, Hegarty SM, Ward C, Walker B, Johnston JA, Olwill SA (2009) Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin Cancer Res 15(19):6042–6051CrossRefPubMed Burden RE, Gormley JA, Jaquin TJ, Small DM, Quinn DJ, Hegarty SM, Ward C, Walker B, Johnston JA, Olwill SA (2009) Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin Cancer Res 15(19):6042–6051CrossRefPubMed
9.
Zurück zum Zitat Ryschich E, Lizdenis P, Ittrich C, Benner A, Stahl S, Hamann A, Schmidt J, Knolle P, Arnold B, Hämmerling GJ (2006) Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res 66(1):198–211CrossRefPubMed Ryschich E, Lizdenis P, Ittrich C, Benner A, Stahl S, Hamann A, Schmidt J, Knolle P, Arnold B, Hämmerling GJ (2006) Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res 66(1):198–211CrossRefPubMed
10.
Zurück zum Zitat Fernández PL, Farré X, Nadal A, Fernández E, Peiró N, Sloane BF, Shi GP, Chapman HA, Campo E, Cardesa A (2001) Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer 95(1):51–55CrossRefPubMed Fernández PL, Farré X, Nadal A, Fernández E, Peiró N, Sloane BF, Shi GP, Chapman HA, Campo E, Cardesa A (2001) Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer 95(1):51–55CrossRefPubMed
11.
Zurück zum Zitat Fan Q, Wang X, Zhang H, Li C, Fan J, Xu J (2012) Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro. Biochem Biophys Res Commun 425(4):703–710CrossRefPubMed Fan Q, Wang X, Zhang H, Li C, Fan J, Xu J (2012) Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro. Biochem Biophys Res Commun 425(4):703–710CrossRefPubMed
12.
Zurück zum Zitat Wang B, Sun J, Kitamoto S, Yang M, Grubb A, Chapman HA, Kalluri R, Shi G-P (2006) Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 281(9):6020–6029CrossRefPubMed Wang B, Sun J, Kitamoto S, Yang M, Grubb A, Chapman HA, Kalluri R, Shi G-P (2006) Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 281(9):6020–6029CrossRefPubMed
13.
Zurück zum Zitat Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, Brogi E, Brastianos PK, Hahn WC, Holsinger LJ (2014) Analysis of tumour-and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol 16(9):876–888CrossRefPubMedPubMedCentral Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, Brogi E, Brastianos PK, Hahn WC, Holsinger LJ (2014) Analysis of tumour-and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol 16(9):876–888CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Flannery T, McQuaid S, McGoohan C, McConnell RS, McGregor G, Mirakhur M, Hamilton P, Diamond J, Cran G, Walker B (2006) Cathepsin S expression: an independent prognostic factor in glioblastoma tumours—a pilot study. Int J Cancer 119(4):854–860CrossRefPubMed Flannery T, McQuaid S, McGoohan C, McConnell RS, McGregor G, Mirakhur M, Hamilton P, Diamond J, Cran G, Walker B (2006) Cathepsin S expression: an independent prognostic factor in glioblastoma tumours—a pilot study. Int J Cancer 119(4):854–860CrossRefPubMed
15.
Zurück zum Zitat Jobs E, Ingelsson E, Risérus U, Nerpin E, Jobs M, Sundström J, Basu S, Larsson A, Lind L, Ärnlöv J (2011) Association between serum cathepsin S and mortality in older adults. JAMA 306(10):1113–1121CrossRefPubMed Jobs E, Ingelsson E, Risérus U, Nerpin E, Jobs M, Sundström J, Basu S, Larsson A, Lind L, Ärnlöv J (2011) Association between serum cathepsin S and mortality in older adults. JAMA 306(10):1113–1121CrossRefPubMed
16.
Zurück zum Zitat Chang W-SW, Wu H-R, Yeh C-T, Wu C-W, Chang J-Y (2007) Lysosomal cysteine proteinase cathepsin S as a potential target for anti-cancer therapy. J Cancer Mol 3(1):5–14 Chang W-SW, Wu H-R, Yeh C-T, Wu C-W, Chang J-Y (2007) Lysosomal cysteine proteinase cathepsin S as a potential target for anti-cancer therapy. J Cancer Mol 3(1):5–14
17.
Zurück zum Zitat Gautam J, Banskota S, Regmi SC, Ahn S, Jeon YH, Jeong H, Kim SJ, Nam T-G, Jeong B-S, Kim J-A Tryptophan hydroxylase 1 and 5-HT7 receptors preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling. Mol Cancer (under revision) Gautam J, Banskota S, Regmi SC, Ahn S, Jeon YH, Jeong H, Kim SJ, Nam T-G, Jeong B-S, Kim J-A Tryptophan hydroxylase 1 and 5-HT7 receptors preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling. Mol Cancer (under revision)
18.
Zurück zum Zitat Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8(4):S55–S61CrossRefPubMed Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8(4):S55–S61CrossRefPubMed
19.
Zurück zum Zitat Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM (2007) High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 67(7):2932–2937CrossRefPubMed Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM (2007) High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 67(7):2932–2937CrossRefPubMed
20.
Zurück zum Zitat Subbarao Sreedhar A, Kalmár É, Csermely P, Shen Y-F (2004) Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 562(1–3):11–15CrossRef Subbarao Sreedhar A, Kalmár É, Csermely P, Shen Y-F (2004) Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 562(1–3):11–15CrossRef
21.
Zurück zum Zitat Bae YK, Kim A, Kim MK, Choi JE, Kang SH, Lee SJ (2013) Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum Pathol 44(10):2028–2037CrossRefPubMed Bae YK, Kim A, Kim MK, Choi JE, Kang SH, Lee SJ (2013) Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum Pathol 44(10):2028–2037CrossRefPubMed
22.
Zurück zum Zitat Choi JE, Kang SH, Lee SJ, Bae YK (2015) Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 22(1):82–89CrossRefPubMed Choi JE, Kang SH, Lee SJ, Bae YK (2015) Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 22(1):82–89CrossRefPubMed
23.
Zurück zum Zitat Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M (2007) Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 5(2):195–201CrossRefPubMed Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M (2007) Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 5(2):195–201CrossRefPubMed
24.
Zurück zum Zitat McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM (2010) Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 10:S59–S65CrossRefPubMed McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM (2010) Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 10:S59–S65CrossRefPubMed
25.
Zurück zum Zitat Jang J-Y, Jeon Y-K, Kim C-W (2010) Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells. BMC Cancer 10(1):391CrossRefPubMedPubMedCentral Jang J-Y, Jeon Y-K, Kim C-W (2010) Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells. BMC Cancer 10(1):391CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Santagata S, Hu R, Lin NU, Mendillo ML, Collins LC, Hankinson SE, Schnitt SJ, Whitesell L, Tamimi RM, Lindquist S (2011) High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci 108(45):18378–18383CrossRefPubMedPubMedCentral Santagata S, Hu R, Lin NU, Mendillo ML, Collins LC, Hankinson SE, Schnitt SJ, Whitesell L, Tamimi RM, Lindquist S (2011) High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci 108(45):18378–18383CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Geraghty P, Greene CM, O’Mahony M, O’Neill SJ, Taggart CC, McElvaney NG (2007) Secretory leucocyte protease inhibitor inhibits interferon-γ-induced cathepsin s expression. J Biol Chem 282(46):33389–33395CrossRefPubMed Geraghty P, Greene CM, O’Mahony M, O’Neill SJ, Taggart CC, McElvaney NG (2007) Secretory leucocyte protease inhibitor inhibits interferon-γ-induced cathepsin s expression. J Biol Chem 282(46):33389–33395CrossRefPubMed
28.
Zurück zum Zitat Lee TKW, Cheung VCH, Lu P, Lau EYT, Ma S, Tang KH, Tong M, Lo J, Ng IOL (2014) Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 60(1):179–191CrossRefPubMed Lee TKW, Cheung VCH, Lu P, Lau EYT, Ma S, Tang KH, Tong M, Lo J, Ng IOL (2014) Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 60(1):179–191CrossRefPubMed
29.
Zurück zum Zitat Graham TR, Odero-Marah VA, Chung LW, Agrawal KC, Davis R, Abdel-Mageed AB (2009) PI3K/Akt-dependent transcriptional regulation and activation of BMP-2-Smad signaling by NF-κB in metastatic prostate cancer cells. Prostate 69(2):168–180CrossRefPubMedPubMedCentral Graham TR, Odero-Marah VA, Chung LW, Agrawal KC, Davis R, Abdel-Mageed AB (2009) PI3K/Akt-dependent transcriptional regulation and activation of BMP-2-Smad signaling by NF-κB in metastatic prostate cancer cells. Prostate 69(2):168–180CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Aggarwal BB, Vijayalekshmi R, Sung B (2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15(2):425–430CrossRefPubMed Aggarwal BB, Vijayalekshmi R, Sung B (2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15(2):425–430CrossRefPubMed
31.
Zurück zum Zitat Liu P, Wilson MJ (2012) miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-κB factor in human fibrosarcoma cells. J Cell Physiol 227(2):867–876CrossRefPubMedPubMedCentral Liu P, Wilson MJ (2012) miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-κB factor in human fibrosarcoma cells. J Cell Physiol 227(2):867–876CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Cheng XW, Shi G-P, Kuzuya M, Sasaki T, Okumura K, Murohara T (2012) Role for cysteine protease cathepsins in heart disease focus on biology and mechanisms with clinical implication. Circulation 125(12):1551–1562CrossRefPubMed Cheng XW, Shi G-P, Kuzuya M, Sasaki T, Okumura K, Murohara T (2012) Role for cysteine protease cathepsins in heart disease focus on biology and mechanisms with clinical implication. Circulation 125(12):1551–1562CrossRefPubMed
33.
Zurück zum Zitat McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta (BBA)—Mol Cell Res 1773(8):1263–1284CrossRef McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta (BBA)—Mol Cell Res 1773(8):1263–1284CrossRef
34.
Zurück zum Zitat Lee S-J, Namkoong S, Kim Y-M, Kim C-K, Lee H, Ha K-S, Chung H-T, Kwon Y-G, Kim Y-M (2006) Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK-and PI3K/Akt/eNOS-dependent signal pathways. Am J Physiol Heart Circ Physiol 291(6):H2836–H2846CrossRefPubMed Lee S-J, Namkoong S, Kim Y-M, Kim C-K, Lee H, Ha K-S, Chung H-T, Kwon Y-G, Kim Y-M (2006) Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK-and PI3K/Akt/eNOS-dependent signal pathways. Am J Physiol Heart Circ Physiol 291(6):H2836–H2846CrossRefPubMed
35.
Zurück zum Zitat Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Yamanoshita O, Iida M, Ohgami N, Tamura H, Kawamoto Y (2011) RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract 2012 Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Yamanoshita O, Iida M, Ohgami N, Tamura H, Kawamoto Y (2011) RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract 2012
Metadaten
Titel
Up-regulation of cathepsin S expression by HSP90 and 5-HT7 receptor-dependent serotonin signaling correlates with triple negativity of human breast cancer
verfasst von
Jaya Gautam
Young Kyung Bae
Jung-Ae Kim
Publikationsdatum
27.10.2016
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-4027-1

Weitere Artikel der Ausgabe 1/2017

Breast Cancer Research and Treatment 1/2017 Zur Ausgabe

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.